Status:
ACTIVE_NOT_RECRUITING
The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer
Lead Sponsor:
Jinming Yu
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to evaluate the predictive value of proteome profiling for brain metastasis in limited-stage small-cell lung cancer
Detailed Description
Small-cell lung cancer (SCLC) constitutes approximately 15% of all lung cancer cases and is characterized by a highly aggressive disease course and poor prognosis. The brain is the most common metasta...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- Histological / pathologic proved limited-stage small-cell lung cancer
- Achieved a complete response (CR) or partial response (PR) after first-line CRT
Exclusion
- Simultaneous participation in another clinical trial
- Brain MRI was not performed during treatment and follow-up
- The follow-up time was less than 2 years
- Patients presenting with other known malignancies for which they are receiving treatment
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 30 2025
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT06483919
Start Date
October 1 2023
End Date
January 30 2025
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Cancer Hospital and Institute
Jinan, Shandong, China, 250000